suance of common stock 445,247 112,830 (19,492)
Proceeds from secured notes
payable 700,000 -
Redemption of Series B
Preferred shares (50,000) - -
Principal payments of notes
payable (647,215) (326,724) (166,515)
Principal payments of
convertible promissory notes (1,000,000)
Principal payments of
capital lease obligations (196,349) (249,738) (272,347)
Net cash provided by
(used in) financing
activities (1,448,317) 236,368 (458,354)
Net increase (decrease) in
cash and cash equivalents 1,317,893 1,921,489 (236,944)
Cash and cash equivalents at
beginning of the year 3,078,052 1,156,563 1,393,507
Cash and cash equivalents at
end of the year $4,395,945 $3,078,052 $1,156,563
'/>"/>SOURCE Photonic Products Group, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1.
Professor Straufs research is Nature Photonics cover article2.
3-D photonic crystals will revolutionize telecommunications3.
Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique4.
China Biopharma Reaches Agreement with a Regional Pharma to Launch New Pharmaceutical Products5.
Live Demos With Hydrogen, New Fuel Cell Products6.
China Biologic Products Announces One of Its R&D Projects Has Been Listed In National Torch Plan7.
Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products8.
iCAD to Feature New Products and Capabilities at European Congress of Radiology9.
New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)10.
China Biologic Products Commences Trading on OTC Bulletin Board11.
Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products